Cargando…
Management of Favorable-risk Advanced Renal Cell Carcinoma: Is Dual Therapy the Answer?
Autores principales: | Kartolo, Adi, Procopio, Giuseppe, Vera-Badillo, Francisco E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317808/ https://www.ncbi.nlm.nih.gov/pubmed/34337547 http://dx.doi.org/10.1016/j.euros.2021.06.006 |
Ejemplares similares
-
The Decision to Surgically Resect Recurrent Renal Cell Carcinoma: More Evidence that Careful Case Selection by Surgeons Is Associated with Better Survival
por: Russo, Paul
Publicado: (2023) -
Management of Late Relapses in Metastatic Testicular Germ Cell Tumors: Still a Challenge
por: Heidenreich, Axel
Publicado: (2021) -
Everolimus treatment in advanced solid tumors: a personal view
por: Pusceddu, Sara, et al.
Publicado: (2015) -
Management of Barrett’s Esophagus: Practice-Oriented Answers to Clinical Questions
por: Zagari, Rocco Maurizio, et al.
Publicado: (2023) -
Lower Urinary Tract Symptoms: A Unique Platform for Urologists’ Fundamental Role in Overall Health
por: Monaghan, Thomas F., et al.
Publicado: (2020)